Related Experiment Video

Updated: Aug 17, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Motor neuron disease associated with carcinoma. A report of 2 cases

M C Gritzman, V U Fritz, S Perkins

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |February 19, 1983
    PubMed

    More Related Videos

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration06:35

    In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

    Published on: June 15, 2018

    Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models08:57

    Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

    Published on: May 17, 2024

    Related Concept Videos

    Mouse Models of Cancer Study02:43

    Mouse Models of Cancer Study

    Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
    The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Myasthenia Gravis: Diagnostic Tests01:15

    Myasthenia Gravis: Diagnostic Tests

    Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
    The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
    Myasthenia Gravis ll: Pathophysiology01:22

    Myasthenia Gravis ll: Pathophysiology

    The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...